Connect your AI

Bristol-Myers Squibb BMY Total Equity

Total Equity at other companies

PfizerPFE

$90.1B-0.3%

Johnson & JohnsonJNJ

$84.97B+8.3%

Merck & Co.MRK

$45.88B-5.1%

IncyteINCY

$5.62B+53.3%

Gilead SciencesGILD

$23.52B+22.7%

Oruka Therapeutics, Inc.ORKA

$486.72M+33.4%

Other financials

Income statement

Revenue$11.5B+2.6%

Gross profit$8.1B-1.2%

Net income$2.7B+9.0%

EPS (diluted)$1.31+9.2%

Balance sheet

Cash & equivalents$9.6B-12.0%

Total debt$44.7B-10.5%

Total assets$86.5B-6.4%

Cash flow

Operating cash flow$1.1B-43.5%

CapEx$347.0M+33.5%

Free cash flow$757.0M-55.3%

Valuation

Market cap$125.61B+26.1%

Enterprise value$160.69B+17.8%

P/E17.3×-2.7×

P/S2.6×+0.5×

Profitability

Gross margin70.5%0.0pp

Net margin15%+3.8pp

FCF margin24.6%-2.9pp

Returns & leverage

Return on equity38.8%+7.3pp

Debt / equity2.2×-0.6×

Current ratio1.4×+0.1×

Where this comes from

Reported directly by Bristol-Myers Squibb in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Bristol-Myers Squibb’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bristol-Myers Squibb's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Bristol-Myers Squibb's total equity?: Bristol-Myers Squibb (BMY) reported total equity of $20.07B in Q1 2026.
How has Bristol-Myers Squibb's total equity changed year-over-year?: Bristol-Myers Squibb's total equity increased by 15.4% year-over-year, from $17.39B to $20.07B.
What is the long-term trend for Bristol-Myers Squibb's total equity?: Over 5 years (2020 to 2025), Bristol-Myers Squibb's total equity has grown at a -13.4% compound annual growth rate (CAGR), from $37.82B to $18.47B.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.